Why we work with pharma
To find a cure fast we need to work in collaboration with all stakeholders, including pharmaceutical and biotechnology companies. We select partners who work in the field of non-Hodgkin Lymphoma, and who often have a particular focus on follicular lymphoma, whose engagement reflects a commitment to understanding the patient perspective and collaborating constructively with patient groups like the FLF.
Our strategy, activities or information will not be influenced by our workings with Pharmaceutical Industry partners/collaborators.
We are grateful to the companies that support our mission and help make these vital programs possible.
Read our policy on working with the pharmaceutical industry here.
Pharma Company & Funding Amount
Kite Pharma – $20,000
- Uniting Experts, Patients, and Innovation in Follicular Lymphoma, to seek a Cure in an Integrated Program
- Webinar Series 1
BeiGene – $96,880
- Discrete Choice Experiment
- FL Biomarker Discovery Program
- Webinar Series 1
AbbVie – $15,000
- FL Biomarker Discovery Program
Genmab/AbbVie – $76,000
- Uniting Experts, Patients, and Innovation in Follicular Lymphoma, to seek a Cure in an Integrated Program
- Pioneering the Future of Immuno-Oncology in Follicular Lymphoma
- Webinar Series 1
AstraZeneca – $35,000
- Uniting Experts, Patients, and Innovation in Follicular Lymphoma, to seek a Cure in an Integrated Program
Novartis Pharma AG – $23,000
- Webinar Series 1
Ipsen Innovation SAS – €5,000
- Clinical Trials Webinar
BioInvent International – €5,000
- Clinical Trials Webinar
Jassen Pharmacuetica – €15,000
- Pioneering the Future of Immuno-Oncology in Follicular Lymphoma